These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Mpl receptor expressed on endothelial cells does not contribute significantly to the regulation of circulating thrombopoietin levels. Geddis AE; Fox NE; Kaushansky K Exp Hematol; 2006 Jan; 34(1):82-6. PubMed ID: 16413394 [TBL] [Abstract][Full Text] [Related]
3. Dual effects of adenovirus-mediated thrombopoietin gene transfer on hepatic oval cell proliferation and platelet counts. Ichiba M; Shimomura T; Murai R; Hashiguchi K; Saeki T; Yoshida Y; Kanbe T; Tanabe N; Tsuchiya H; Miura N; Tajima F; Kurimasa A; Hamada H; Shiota G Biochem Biophys Res Commun; 2005 Sep; 335(3):723-9. PubMed ID: 16087157 [TBL] [Abstract][Full Text] [Related]
4. Adenoviral gene transfer with soluble vascular endothelial growth factor receptors impairs angiogenesis and perfusion in a murine model of hindlimb ischemia. Jacobi J; Tam BY; Wu G; Hoffman J; Cooke JP; Kuo CJ Circulation; 2004 Oct; 110(16):2424-9. PubMed ID: 15477417 [TBL] [Abstract][Full Text] [Related]
5. An overview of thrombopoietin: with a historical perspective. Levin J C R Acad Sci III; 1995 May; 318(5):609-18. PubMed ID: 7671007 [TBL] [Abstract][Full Text] [Related]
6. IL-3 does not contribute to platelet production in c-Mpl-deficient mice. Chen Q; Solar G; Eaton DL; de Sauvage FJ Stem Cells; 1998; 16 Suppl 2():31-6. PubMed ID: 11012175 [TBL] [Abstract][Full Text] [Related]
7. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371 [TBL] [Abstract][Full Text] [Related]
8. Impact of chicken thrombopoietin and its receptor c-Mpl on hematopoietic cell development. Bartunek P; Karafiat V; Bartunkova J; Pajer P; Dvorakova M; Kralova J; Zenke M; Dvorak M Exp Hematol; 2008 Apr; 36(4):495-505. PubMed ID: 18243490 [TBL] [Abstract][Full Text] [Related]
9. [Biology of thrombopoietin and its receptors]. Robak T Postepy Hig Med Dosw; 1996; 50(6):649-63. PubMed ID: 9064684 [TBL] [Abstract][Full Text] [Related]
10. Augmentation of blood platelet levels by intratracheal administration of an adenovirus vector encoding human thrombopoietin cDNA. Cannizzo SJ; Frey BM; Raffi S; Moore MA; Eaton D; Suzuki M; Singh R; Mack CA; Crystal RG Nat Biotechnol; 1997 Jun; 15(6):570-3. PubMed ID: 9181581 [TBL] [Abstract][Full Text] [Related]
11. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Yang C; Li YC; Kuter DJ Br J Haematol; 1999 May; 105(2):478-85. PubMed ID: 10233424 [TBL] [Abstract][Full Text] [Related]
12. Compared effects of Mpl ligand and other cytokines on human MK differentiation. Vitrat N; Cohen-Solal K; Norol F; Guichard J; Cramer E; Vainchenker W; Wendling F; Debili N Stem Cells; 1998; 16 Suppl 2():37-51. PubMed ID: 11012176 [TBL] [Abstract][Full Text] [Related]
13. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Bunting S; Widmer R; Lipari T; Rangell L; Steinmetz H; Carver-Moore K; Moore MW; Keller GA; de Sauvage FJ Blood; 1997 Nov; 90(9):3423-9. PubMed ID: 9345025 [TBL] [Abstract][Full Text] [Related]
14. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031 [TBL] [Abstract][Full Text] [Related]
15. Megakaryocyte development and platelet production. Deutsch VR; Tomer A Br J Haematol; 2006 Sep; 134(5):453-66. PubMed ID: 16856888 [TBL] [Abstract][Full Text] [Related]
16. Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: critical role of the inflammatory/arteriogenic pathway. Fujii T; Yonemitsu Y; Onimaru M; Tanii M; Nakano T; Egashira K; Takehara T; Inoue M; Hasegawa M; Kuwano H; Sueishi K Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2483-9. PubMed ID: 16960104 [TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin (TPO) induces c-myc expression through a PI3K- and MAPK-dependent pathway that is not mediated by Akt, PKCzeta or mTOR in TPO-dependent cell lines and primary megakaryocytes. Chanprasert S; Geddis AE; Barroga C; Fox NE; Kaushansky K Cell Signal; 2006 Aug; 18(8):1212-8. PubMed ID: 16380230 [TBL] [Abstract][Full Text] [Related]
18. [Thrombopoietin and megakaryocyte differentiation]. Vainchenker W; Debili N; Norol F; Wendling F Schweiz Med Wochenschr; 1998 Oct; 128(42):1575-81. PubMed ID: 9824885 [TBL] [Abstract][Full Text] [Related]
19. [Megakaryocyte development and platelet production in normal and disease states]. Deutsch V; Katz BZ; Tomer A Harefuah; 2010 May; 149(5):291-7, 336. PubMed ID: 20929068 [TBL] [Abstract][Full Text] [Related]
20. High-level expression of Mpl in platelets and megakaryocytes is independent of thrombopoietin. Cohen-Solal K; Vitrat N; Titeux M; Vainchenker W; Wendling F Blood; 1999 May; 93(9):2859-66. PubMed ID: 10216080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]